208 related articles for article (PubMed ID: 31837441)
1. Application of physiologically based kinetic (PBK) modelling in the next generation risk assessment of dermally applied consumer products.
Moxon TE; Li H; Lee MY; Piechota P; Nicol B; Pickles J; Pendlington R; Sorrell I; Baltazar MT
Toxicol In Vitro; 2020 Mar; 63():104746. PubMed ID: 31837441
[TBL] [Abstract][Full Text] [Related]
2. A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products.
Baltazar MT; Cable S; Carmichael PL; Cubberley R; Cull T; Delagrange M; Dent MP; Hatherell S; Houghton J; Kukic P; Li H; Lee MY; Malcomber S; Middleton AM; Moxon TE; Nathanail AV; Nicol B; Pendlington R; Reynolds G; Reynolds J; White A; Westmoreland C
Toxicol Sci; 2020 Jul; 176(1):236-252. PubMed ID: 32275751
[TBL] [Abstract][Full Text] [Related]
3. Next generation risk assessment for occupational chemical safety - A real world example with sodium-2-hydroxyethane sulfonate.
Wood A; Breffa C; Chaine C; Cubberley R; Dent M; Eichhorn J; Fayyaz S; Grimm FA; Houghton J; Kiwamoto R; Kukic P; Lee M; Malcomber S; Martin S; Nicol B; Reynolds J; Riley G; Scott S; Smith C; Westmoreland C; Wieland W; Williams M; Wolton K; Zellmann T; Gutsell S
Toxicology; 2024 Jun; 506():153835. PubMed ID: 38857863
[TBL] [Abstract][Full Text] [Related]
4. The margin of internal exposure (MOIE) concept for dermal risk assessment based on oral toxicity data - A case study with caffeine.
Bessems JGM; Paini A; Gajewska M; Worth A
Toxicology; 2017 Dec; 392():119-129. PubMed ID: 28288858
[TBL] [Abstract][Full Text] [Related]
5. A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment.
Alexander-White C; Bury D; Cronin M; Dent M; Hack E; Hewitt NJ; Kenna G; Naciff J; Ouedraogo G; Schepky A; Mahony C; Europe C
Regul Toxicol Pharmacol; 2022 Mar; 129():105094. PubMed ID: 34990780
[TBL] [Abstract][Full Text] [Related]
6. A hypothetical skin sensitisation next generation risk assessment for coumarin in cosmetic products.
Reynolds G; Reynolds J; Gilmour N; Cubberley R; Spriggs S; Aptula A; Przybylak K; Windebank S; Maxwell G; Baltazar MT
Regul Toxicol Pharmacol; 2021 Dec; 127():105075. PubMed ID: 34728330
[TBL] [Abstract][Full Text] [Related]
7. Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients.
Gilmour N; Kern PS; Alépée N; Boislève F; Bury D; Clouet E; Hirota M; Hoffmann S; Kühnl J; Lalko JF; Mewes K; Miyazawa M; Nishida H; Osmani A; Petersohn D; Sekine S; van Vliet E; Klaric M
Regul Toxicol Pharmacol; 2020 Oct; 116():104721. PubMed ID: 32645429
[TBL] [Abstract][Full Text] [Related]
8. New framework for a non-animal approach adequately assures the safety of cosmetic ingredients - A case study on caffeine.
Bury D; Alexander-White C; Clewell HJ; Cronin M; Desprez B; Detroyer A; Efremenko A; Firman J; Hack E; Hewitt NJ; Kenna G; Klaric M; Lester C; Mahony C; Ouedraogo G; Paini A; Schepky A;
Regul Toxicol Pharmacol; 2021 Jul; 123():104931. PubMed ID: 33905778
[TBL] [Abstract][Full Text] [Related]
9. PBK modelling of topical application and characterisation of the uncertainty of C
Li H; Reynolds J; Sorrell I; Sheffield D; Pendlington R; Cubberley R; Nicol B
Toxicol Appl Pharmacol; 2022 May; 442():115992. PubMed ID: 35346730
[TBL] [Abstract][Full Text] [Related]
10. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
[TBL] [Abstract][Full Text] [Related]
11. Human biomonitoring and toxicokinetics as key building blocks for next generation risk assessment.
Reale E; Zare Jeddi M; Paini A; Connolly A; Duca R; Cubadda F; Benfenati E; Bessems J; S Galea K; Dirven H; Santonen T; M Koch H; Jones K; Sams C; Viegas S; Kyriaki M; Campisi L; David A; Antignac JP; B Hopf N
Environ Int; 2024 Feb; 184():108474. PubMed ID: 38350256
[TBL] [Abstract][Full Text] [Related]
12. Read-across and new approach methodologies applied in a 10-step framework for cosmetics safety assessment - A case study with parabens.
Ouedraogo G; Alexander-White C; Bury D; Clewell HJ; Cronin M; Cull T; Dent M; Desprez B; Detroyer A; Ellison C; Giammanco S; Hack E; Hewitt NJ; Kenna G; Klaric M; Kreiling R; Lester C; Mahony C; Mombelli E; Naciff J; O'Brien J; Schepky A; Tozer S; van der Burg B; van Vugt-Lussenburg B; Stuard S; Cosmetics Europe
Regul Toxicol Pharmacol; 2022 Jul; 132():105161. PubMed ID: 35508214
[TBL] [Abstract][Full Text] [Related]
13. Next Generation Risk Assessment of the Anti-Androgen Flutamide Including the Contribution of Its Active Metabolite Hydroxyflutamide.
van Tongeren TCA; Carmichael PL; Rietjens IMCM; Li H
Front Toxicol; 2022; 4():881235. PubMed ID: 35722059
[TBL] [Abstract][Full Text] [Related]
14. Aggregate exposure modelling of zinc pyrithione in rinse-off personal cleansing products using a person-orientated approach with market share refinement.
Tozer SA; Kelly S; O'Mahony C; Daly EJ; Nash JF
Food Chem Toxicol; 2015 Sep; 83():103-10. PubMed ID: 26092325
[TBL] [Abstract][Full Text] [Related]
15. Next generation risk assessment for skin allergy: Decision making using new approach methodologies.
Gilmour N; Reynolds J; Przybylak K; Aleksic M; Aptula N; Baltazar MT; Cubberley R; Rajagopal R; Reynolds G; Spriggs S; Thorpe C; Windebank S; Maxwell G
Regul Toxicol Pharmacol; 2022 Jun; 131():105159. PubMed ID: 35311660
[TBL] [Abstract][Full Text] [Related]
16. Use of Physiologically-Based Kinetics Modelling to Reliably Predict Internal Concentrations of the UV Filter, Homosalate, After Repeated Oral and Topical Application.
Najjar A; Schepky A; Krueger CT; Dent M; Cable S; Li H; Grégoire S; Roussel L; Noel-Voisin A; Hewitt NJ; Cardamone E
Front Pharmacol; 2021; 12():802514. PubMed ID: 35058784
[TBL] [Abstract][Full Text] [Related]
17. ADME characterization and PBK model development of 3 highly protein-bound UV filters through topical application.
Li H; Bunglawala F; Hewitt NJ; Pendlington R; Cubberley R; Nicol B; Spriggs S; Baltazar M; Cable S; Dent M
Toxicol Sci; 2023 Oct; 196(1):1-15. PubMed ID: 37584694
[TBL] [Abstract][Full Text] [Related]
18. Application of physiologically-based toxicokinetic modelling in oral-to-dermal extrapolation of threshold doses of cosmetic ingredients.
Gajewska M; Worth A; Urani C; Briesen H; Schramm KW
Toxicol Lett; 2014 Jun; 227(3):189-202. PubMed ID: 24731971
[TBL] [Abstract][Full Text] [Related]
19. Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making.
Paini A; Leonard JA; Joossens E; Bessems JGM; Desalegn A; Dorne JL; Gosling JP; Heringa MB; Klaric M; Kliment T; Kramer NI; Loizou G; Louisse J; Lumen A; Madden JC; Patterson EA; Proença S; Punt A; Setzer RW; Suciu N; Troutman J; Yoon M; Worth A; Tan YM
Comput Toxicol; 2019 Feb; 9():61-72. PubMed ID: 31008414
[TBL] [Abstract][Full Text] [Related]
20. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.
Najjar A; Punt A; Wambaugh J; Paini A; Ellison C; Fragki S; Bianchi E; Zhang F; Westerhout J; Mueller D; Li H; Shi Q; Gant TW; Botham P; Bars R; Piersma A; van Ravenzwaay B; Kramer NI
Arch Toxicol; 2022 Dec; 96(12):3407-3419. PubMed ID: 36063173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
